Board of Directors

Hugh Rosen, M.D., Ph.D.

Hugh Rosen, M.D., Ph.D., joins ActivX as President and Chairman with a 30+ year career in the pharmaceutical, biotechnology and academic sectors. Hugh’s career has been one of significant achievements. Following training in medicine in Cape Town, he received his D.Phil. as a Royal Commission for the Exhibition of 1851 Scholar at the University of Oxford. He then spent 11 years at Merck Research Laboratories before becoming a Professor at The Scripps Research Institute (TSRI) in 2002. At TSRI, his research focus has been on chemical and biological approaches to the molecular mechanisms regulating lymphocyte trafficking. As part of this research, he co-invented ozanimod with the Edward Roberts lab and was a scientific founder of Receptos, which was acquired by Celgene in 2015 for $7.3 Billion. Hugh is also a scientific founder of BlackThorn Therapeutics which recently closed a $40M Series A. He serves as an independent Board member at Regulus Therapeutics and will also remain on the faculty of TSRI.

John Kozarich, Ph.D

Dr. Kozarich joins ActivX with over 20 years experience in academic and pharmaceutical research. Most recently, he was Vice President at Merck Research Laboratories, where he was responsible for programs including antimicrobial drug discovery, enzymology, 5a-reductase biology, lipid biochemistry, nuclear receptors, ion channels and structural biology. He has been involved in a number of Merck drug programs, including Propecia, Type-1 5a-reductase inhibitor, and MRSA carbapenams. He also has had primary responsibility for a number of Merck collaborations with biotechnology companies, such as Aurora Biosciences, Cubist and KaroBio. In addition, he has played a major role in Merck's acquisition of SIBIA and in the development of its new Boston Research Center. Previously, Dr. Kozarich held faculty positions at the University of Maryland, College Park, and Yale University School of Medicine. He also served as Vice President, Research and Development at Alkermes, a biotechnology company that develops products based on sophisticated drug delivery technologies. Dr. Kozarich is internationally known for his work on enzyme mechanisms and on the chemistry of DNA cleaving antitumor drugs. He was an American Cancer Society Faculty Research Awardee and in 1988 received the Pfizer Award in Enzyme Chemistry of the American Chemical Society for his unique and broad research contributions. He has also served on numerous government and academic committees. Dr. Kozarich has authored over 125 primary scientific publications and holds three patents.

Yoh Ito

Mr. Yoh Ito, Vice President and Chief Financial Officer of ActivX, is also the Director of Finance & Accounting of Kyorin Pharmaceutical Co. Ltd. He joined Kyorin in 2003 and previously held the position of Senior Manager of Strategies & Business Development Headquarters. Prior to Kyorin, Mr. Ito was Managing Director of Capital Arts, Inc. He received his MBA from Cornell University and graduated from the University of Tokyo.

Shigeru Ogihara

Executive Director of Kyorin Pharmaceutical, Ltd.

Mr. Shigeru Ogihara joined Kyorin Pharmaceutical, Ltd. in 1979 and is currently Executive Director of Kyorin Pharmaceutical, Ltd. and Kyorin Holdings, Inc. He worked for Kyorin Rimedio Co., Ltd. from 2010-2014 as Executive Director, and then as President and Chief Executive Officer from 2011-2014. He is still Executive Director of Kyorin Rimedio. Prior to Kyorin Rimedio, Mr. Ogihara worked for Kyorin Pharmaceutical, Ltd. from 1979-2009. He was Director of Consumer Healthcare from 2002-2003 and Director of Life Cycle Management Division from 2004-2009. He also worked in the Planning and Development Division, Research Laboratories and Sales and Marketing Division. Mr. Ogihara received his BS from Tokyo University of Pharmacy and Life Sciences, School of Pharmacy.

Koichiro Hagihara, Ph.D.

Director of Pharmacology, Discovery Research Laboratories of Kyorin Pharmaceutical Co. Ltd.

Dr. Koichiro Hagihara joined Kyorin Pharmaceutical, Ltd. in 2008 and is currently Director of Pharmacology at Kyorin’s Discovery Research Laboratories. Prior to joining Kyorin, Dr. Hagihara was a researcher at Nisshin-Kyorin from 1998 – 2008 and was Director of Research Laboratories in Nisshin-Kyorin Pharmaceutical from 2006-2008. Prior to Nisshin-Kyorin, he worked for Nisshin Flour Milling from 1983-1998. Dr. Hagihara received his Ph.D. from Osaka University School of Medicine in 1995 and his BS from Kyoto University, Faculty of Agriculture (Food Science and Technology).

Murakami Koji, Ph.D.

Senior Cooperate Officer of Kyorin Pharmaceutical, Ltd.

Dr. Koji Murakami joined Kyorin Pharmaceutical, Ltd. in 1987 and is currently senior cooperate officer of Kyorin Pharmaceutical, Ltd. He was a researcher at Kyorin’s Discovery Research Laboratories from 1987- 2010 and was Director of Kyorin’s Discovery Research Laboratories from 2011-2015. He is currently a Director of Kyorin’s WATARASE Research Center. Dr. Murakami obtained his BS, and Ph.D. in 2000 from Tokyo University of Pharmacy and Life Science.

Yanai Makoto, Ph.D.

Senior Director of Business Development of Kyorin Pharmaceutical, Ltd.

Dr. Makoto Yanai joined Kyorin Pharmaceutical, Ltd. in 2008 and is currently Senior Director of Business Development. He worked for Kyorin Europe GmbH from 2012-2016 as Managing Director. Prior to joining Kyorin, Dr. Yanai was a researcher at Nisshin-Kyorin from 1998 – 2008. Prior to Nisshin-Kyorin, he worked for Nisshin Flour Milling from 1985-1998. Dr. Yanai received his Ph.D. from the University of Tokyo, Faculty of Agriculture in 2000 and his BS from the University of Tokyo, Faculty of Agriculture (Agricultural Chemistry), and studied at Stanford University, Department of Chemistry for two years.